Prevalence and Prognostic Impact of MYC, BCL۲, and BCL۶ Rearrangements in Large B Cell Lymphoma Patients: A Multicenter Historical Cohort Study from Iran
- سال انتشار: 1403
- محل انتشار: مجله سرطان خاورمیانه، دوره: 15، شماره: 2
- کد COI اختصاصی: JR_MISJ-15-2_002
- زبان مقاله: انگلیسی
- تعداد مشاهده: 79
نویسندگان
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Molecular Pathology and Cytogenetics, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Molecular Pathology and Cytogenetics, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin's lymphoma, characterized by remarkable molecular heterogeneity. This study evaluates the prevalence of MYC, BCL۲, and BCL۶ gene rearrangements among Iranian DLBCL patients.Method: This historical cohort study encompassed ۱۵۲ patients drawn from six reference hospitals who participated in the research. Interphase dual-color break-apart fluorescence in situ hybridization (FISH) was applied to formalin-fixed paraffin-embedded DLBCL specimens categorized as "not otherwise specified" alongside ۲۰ normal controls. Survival data was analyzed using the Kaplan-Meier method and the Log-Rank test.Results: Among the patients, ۷ (۴.۸%), ۴ (۲.۹%), and ۱۵ (۱۰.۲%) exhibited MYC, BCL۲, and BCL۶ rearrangements, respectively. Additionally, ۱.۵% of the patients demonstrated double-hit (DH) characteristics with both MYC and BCL۲ rearrangements, while no triple rearrangements were observed. The presence of rearrangements appeared to be independent of clinicopathological variables. Patients with rearrangements experienced reduced survival durations, with reductions of ۲۶.۶, ۳۱.۲, ۹.۱, and ۳۴.۲ months for MYC, BCL۲, BCL۶-rearranged, and DH tumors, respectively (P > ۰.۰۵). Adverse prognosis was associated with age, activated B-cell-like phenotype, disease stage, B symptoms, lactate dehydrogenase levels, and risk grouping according to the National Comprehensive Cancer Network (NCCN) International Prognostic Index.Conclusion: DLBCL cases featuring MYC, BCL۲, and/or BCL۶ translocations are relatively rare. Patients harboring these rearrangements tend to exhibit aggressive disease progression with shortened overall survival. However, these differences did not reach statistical significance, necessitating further research to validate the incorporation of such tests into the routine workup of DLBCL patients.کلیدواژه ها
diffuse large B cell lymphoma, gene rearrangement, MYC, BCL۲, BCL۶اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.